According to summaries in product safety descriptions, the risk of AEs associated with TNF inhibitors is relatively low.[8–10] However, severe adverse reactions to anti-TNFα agents have been reported in clinical trials and post-marketing studies for approved indications.[11–13] These adverse effects compromise the immune system, weakening the patient’s ability to resist infections and cancers.[14] Life-threatening and fatal infections, including sepsis, as well as various malignancies, have been documented. This evidence concerns the gene TNF and Sepsis.